Geron stocks.

Geron, CTI rally after leaked data for Legend Biotech’s blood cancer drug. Apr. 19, 2023 2:00 PM ET Geron Corporation (GERN), CTIC JNJ, BMY, LEGN TSVT By: Dulan Lokuwithana, SA News Editor 26 ...12 sept. 2023 ... Geron (GERN) stock is gaining on Tuesday following an upgrade for the biopharmaceutical company's shares from Goldman Sachs.Asterias has ties to a stock promotion and faces a near-term need to raise significant capital. Asterias' pipeline was abandoned by Geron in 2011 after showing no signs of efficacy in its first ...Geron Stock Ownership FAQ. Who owns Geron? Geron (NASDAQ: GERN) is owned by 68.31% institutional shareholders, 1.21% Geron insiders, and 30.48% retail investors. Ra Capital Management LP is the largest individual Geron shareholder, owning 46.20M shares representing 8.51% of the company.

What is Geron's consensus rating and price target? According to the issued ratings of 3 analysts in the last year, the consensus rating for Geron stock is Buy based on the current 3 buy ratings for GERN. The average twelve-month price prediction for Geron is $4.75 with a high price target of $6.00 and a low price target of $4.00.Sep 16, 2022 · Not surprisingly, Geron stock, which had risen to a price of >$6 on the positive IMerge study news, collapsed to <$1. The stock price remained depressed throughout 2020 and 2021, but Geron did not ... Feb 23, 2022 · GERN has a market cap of $334mn and a cash reserve of $215mn. Research and development expenses for the three months ended September 30, 2021 were $18.5 million, while general and administrative ...

0.55%. $93.07B. GERN | Complete Geron Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. Funding. Geron has raised a total of. $599.5M. in funding over 7 rounds. Their latest funding was raised on Jan 5, 2023 from a Post-IPO Equity round. Geron is registered under the ticker NASDAQ:GERN . Geron is funded by 4 investors. Hercules Capital and Silicon Valley Bank are the most recent investors. Unlock for free.

Geron Corporation is a late-stage biopharmaceutical company. The Company is focused on the development and commercialization of imetelstat, a therapeutic for hematologic malignancies. The Company operates through a single segment, which is engaged in the development of therapeutic products for oncology.Stocks trading online may seem like a great way to make money, but if you want to walk away with a profit rather than a big loss, you’ll want to take your time and learn the ins and outs of online investing first. This guide should help get...PURPOSE Patients with myelofibrosis who are relapsed or refractory (R/R) to Janus-associated kinase inhibitors (JAKis) have poor clinical outcomes including dismal overall survival (OS) that ranges between 13 and 16 months. Imetelstat, a telomerase inhibitor, was evaluated in patients with intermediate-2 or high-risk myelofibrosis R/R to …Keros Therapeutics Inc. 30.84. +0.84. +2.80%. Get Geron Corp (GERN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC.

Geron (GERN) delivered earnings and revenue surprises of -12.50% and 79.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Looking at Geron's most recent earnings report, as of June 30, 2023, the company had $400.2M in cash and equivalents. In Q2 2023, Geron received $17.8M from cash exercises of warrants and may ...

Track Geron Corp. (GERN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors See GERN Report. Geron Corporation ( GERN) is near the top in its industry group according to InvestorsObserver. GERN gets an overall rating of 80. That means it scores higher than 80 percent of stocks. Geron Corporation gets a 95 rank in the Biotechnology industry. Biotechnology is number 48 out of 148 industries. GERN has an Overall Score of 80.Robert Spiegel owns over 8,750 units of Geron stock worth over $51,741 and over the last 13 years he sold GERN stock worth over $115,009. In addition, he makes $126,912 as Independent Director at Geron. Wallmine is a radically better financial terminal. Sign up in seconds, it's free!Geron stock has received a consensus rating of buy. The average rating score is and is based on 14 buy ratings, 1 hold ratings, and 0 sell ratings. What was the 52-week low for Geron stock?Geron is a late-stage clinical biopharmaceutical company pursuing therapies with the potential to extend and enrich the lives of patients living with hematologic malignancies. Our first-in-class investigational telomerase inhibitor, imetelstat, harnesses Nobel Prize-winning science in a treatment that may alter the underlying drivers of disease.What is Geron's consensus rating and price target? According to the issued ratings of 3 analysts in the last year, the consensus rating for Geron stock is Buy based on the current 3 buy ratings for GERN. The average twelve-month price prediction for Geron is $4.75 with a high price target of $6.00 and a low price target of $4.00.Shares of Geron Corporation ( NASDAQ: GERN) reached the lowest level since late December on Tuesday after Goldman Sachs launched its coverage with a Neutral view noting that the stock already ...

Goldman Sachs has upgraded Geron Corporation (NASDAQ:GERN) to Buy from Neutral, with a price target of $4.. Recently, the FDA assigned a standard review and a Prescription Drug User Fee Act (PDUFA ...FOSTER CITY, Calif., November 07, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to present at the following investor conferences: Find the latest Geron Corporation (GERN) stock quote, history, news ... Geron shareholders would also receive BioTime stock-purchase warrants presently valued at approximately $13 million. Geron would retain its cancer therapy business, including Imetelstat and GRN1005, and its cash and short-term liquid investments and Geron shareholders would continue to own 100% of the Geron cancer therapy business …6.0%. 10% most volatile stocks in US Market. 15.3%. 10% least volatile stocks in US Market. 2.9%. Stable Share Price: GERN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week. Volatility Over Time: GERN's weekly volatility (8%) has been stable over the past year.Find the latest Geron Corporation (GERN) stock quote, history, news and other vital information to help you with your stock trading and investing.Mar 17, 2023 · The resulting dilution - the share count increased from 327.6m shares to 381m shares, or by ~16%, may explain why Geron stock quickly fell in value, erasing most of the gains triggered by the ...

Geron (NASDAQ:GERN) initiated with Buy rating and $4 ... Look at the things that have stopped rallies in Geron stock and ask yourself why Geron would make such statements ...Aug 22, 2023 · Geron Corporation ( NASDAQ: GERN) announced Tuesday that the U.S. FDA accepted its marketing application for the blood cancer therapy imetelstat, under standard review with a Prescription Drug ...

Geron Stock Performance Shares of NASDAQ GERN opened at $1.99 on Monday. The firm has a fifty day moving average price of $1.90 and a 200-day moving average price of $2.57.2 days ago · What is the target price for Geron (GERN) stock? A. The latest price target for Geron ( NASDAQ: GERN) was reported by Goldman Sachs on Tuesday, September 12, 2023. The analyst firm set a price ... John Scarlett GERN stock SEC Form 4 insiders trading. John has made over 2 trades of the Geron stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 1,340,000 units of GERN stock worth $2,010,000 on 8 February 2023.. The largest trade he's ever made was exercising 1,340,000 units of Geron stock …NVIDIA Corporation Common Stock. $426.835 +2.705 0.64%. MULN. Mullen Automotive, Inc. Common Stock. $0.1588 +0.0579 57.38%. Find the latest on short interest for Geron Corporation Common Stock ...Geron Corporation (NASDAQ:GERN) Q3 2023 Earnings Call Transcript November 2, 2023 Geron Corporation beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. Operator: Good ...There's a lot of hype around biotechnology stocks for their huge potential, but it comes with risks. We cover how to find the best stocks in the biotech sector.Summary. Geron Corporation stock has nearly halved since July, leading to concerns about whether the price will go back up. Geron's telomerase inhibitor imetelstat has a PDUFA on June 16, 2024 ...il y a 10 heures ... This means that the stock's trading pattern over the last month have been neutral. Geron Corp currently has the 131th highest Short-Term ...EVP Chief Operating Officer. 2023-02-09. 150,000. $1.51. $226.50k Buy. 1 of 2. GERN insiders have sold more... subscribe to Premium to read more. Net Insider Buy/Sell (L12M) Ownership. Be the first to know when GERN insiders and whales buy or sell their stock.4 hours ago · In June this year, Geron stock hit its 5-year high value of ~$3.6 per share, after the company shared data at the European Hematology Association annual meeting, showing that 18% of patients in ...

Geron, based in Foster City, California, was founded by gerontologist Mary C. West and Michael D. West, now CEO of AgeX Therapeutics. [2] [3] They secured initial venture capital investments in the company from Kleiner Perkins Caufield & Byers and Venrock. [4] The company was incorporated in 1990 and began doing business in 1992.

Dividends on Geron stock: dividend pay date calendar, dividend per share, dividend payment, dividend historical data, dividend policy, dividend news, dividend schedulet, dividend chart. ... Geron Corporation, a late-stage clinical biopharmaceutical company, ...

During the Class Period, Geron's common stock traded on the Nasdaq under the symbol GERN. Beginning on January 23, 2020, two related securities class actions ...Nov 30, 2023 · Buy biotech stock Geron for a 70% return in 12 months: Goldman Sachs. Sell-off in Geron Corp (NASDAQ: GERN) over the past three months has created a great buying opportunity, says Corinne Jenkins – a Goldman Sachs analyst. Geron shares could shoot up to $4.0 Jenkins upg... 2 months ago - Invezz. Geron Corporation Common Stock (GERN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.FOSTER CITY, Calif., August 21, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA ...Jan 4, 2023 · What To Know: Geron said it intends to sell $175 million of its common stock in an underwritten public offering. The company intends to grant the underwriters a 30-day option to purchase up to an ... Geron Corporation announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs).Summary. Geron will report Q1 2023 earnings this Thursday 11th May. The company may be close to winning a first FDA approval for a drug in its >30-year history. Imetelstat is a differentiated drug ...Geron Corporation (NASDAQ:GERN) Q3 2023 Earnings Call Transcript November 2, 2023 Geron Corporation beats earnings expectations. Reported EPS is $-0.08, expectations …Dividends on Geron stock: dividend pay date calendar, dividend per share, dividend payment, dividend historical data, dividend policy, dividend news, dividend schedulet, dividend chart. ... Geron Corporation, a late-stage clinical biopharmaceutical company, ...Geron Corporation (NASDAQ: GERN) is a late-stage biopharmaceutical firm that targets blood cancers.The main way they achieve this is by inhibiting the enzyme telomerase with their innovative ...Geron, CTI rally after leaked data for Legend Biotech’s blood cancer drug. Apr. 19, 2023 2:00 PM ET Geron Corporation (GERN), CTIC JNJ, BMY, LEGN TSVT By: Dulan Lokuwithana, SA News Editor 26 ...

Geron has seen some favorable Phase II data from their core product pipeline, which helped drive their share price up by ~20% over the past few months. As they continue to believe final results ...Arming decision-makers in tech, business and public policy with the unbiased, fact-based news and analysis they need to navigate a world in rapid change.Dec 1, 2023 · Dollar Volume Sold Short. $86.29 million. Short Interest Ratio / Days to Cover. 7.9. Last Record Date. November 15, 2023. Outstanding Shares. Geron Corporation Common Stock (GERN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Instagram:https://instagram. companies similar to charles schwabbest options trading booksj.b. hunt transport services incstocks for dollar4 On top of that, Geron is studying if Imetelstat can also be used for other types of treatment, such as for refractory myelofibrosis or other related disorders. Geron thinks that its Imetelstat sales could reach as much as $3 billion annually by 2030. That’s a huge number for a stock that has a market cap of just $1.3 billion right now. otcmkts sgtmwheelchair tennis us open In June this year, Geron stock hit its 5-year high value of ~$3.6 per share, after the company shared data at the European Hematology Association annual meeting, showing that 18% of patients in ... gdx dividend Geron has generated ($0.34) earnings per share over the last year ( ($0.34) diluted earnings per share). Earnings for Geron are expected to grow in the coming year, from ($0.35) to ($0.31) per share. Geron has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 21st, 2024 based ...Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools. Identify stocks that meet your criteria using seven unique stock screeners.Geron Corp. (GERN) and CTI Bio (CTIC) were among notable gainers in the blood cancer space after leaked data for multiple myeloma therapy Carvykti . Read more here.